Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Obesity

Free Subscription Articles published in Metabolism Retrieve available abstracts of 93 articles: HTML format

Single Articles

December 2025
1. GIANNAKOGEORGOU A, Kahl S, Granata C, Heilmann G, et al
   Relationship of GDF15 with hepatic mitochondrial respiration is depending on the presence of fibrosis in obese individuals.
   Metabolism. 2025;173:156391.
   PubMed     Abstract available
   
   
   
2. GUO DF, Luo Z, Olson A, Morgan DA, et al
   SerpinA3N in leptin-sensitive neurons is required for energy and glucose homeostasis and autonomic regulation.
   Metabolism. 2025;173:156387.
   PubMed     Abstract available
   
   
   September 2025
3. PHILIPPE MA, Fruchet B, Cagninacci L, Beaudoin L, et al
   BMAL2 controls adipose tissue inflammation and metabolic adaptation during obesity.
   Metabolism. 2025 Sep 20:156396. doi: 10.1016/j.metabol.2025.156396.
   PubMed     Abstract available
   
   
   
4. DOS REIS ARAUJO T, da Silva Junior JA, Alves BL, Guimaraes DSPSF, et al
   Disruption of mitochondria-associated membranes contributes to the dysregulation of insulin secretion in undernutrition, obesity, and double burden of malnutrition.
   Metabolism. 2025 Sep 15:156393. doi: 10.1016/j.metabol.2025.156393.
   PubMed     Abstract available
   
   
   
5. LIU J, Oliverio A, Godlewski G, Kocvarova R, et al
   Hepatic CB1 receptor signaling triggers G(i/o)alpha-mediated lipolysis in lean mice but G(s)alpha-mediated lipogenesis in obese mice.
   Metabolism. 2025;170:156308.
   PubMed     Abstract available
   
   
   
6. CUTHBERTSON DJ, Kennedy OJ, Bilson J, Hydes TJ, et al
   Impact of metabolic dysfunction severity in steatotic liver disease and its interaction with liver fibrosis on all-cause mortality and multiple hepatic and extra-hepatic outcomes.
   Metabolism. 2025;170:156306.
   PubMed     Abstract available
   
   
   
7. BHATTACHARJEE P, Dvoracsko S, Pointeau O, Kundu B, et al
   Evaluation of tetrahydropyridazine-based peripherally restricted dual inhibitors of CB1R and inducible nitric oxide synthase (iNOS) for treating metabolic syndrome disorders.
   Metabolism. 2025;170:156291.
   PubMed     Abstract available
   
   
   August 2025
8. ZHANG XD, Zhong YS, Yan H, Jin LH, et al
   Chemical discovery of a novel MD2/ADAM17 dual-target inhibitor as a potential therapeutic candidate for saturated fatty acid-induced myocardial inflammatory injury.
   Metabolism. 2025;169:156298.
   PubMed     Abstract available
   
   
   
9. LEE YH, Lee J, Jeong J, Park K, et al
   Hepatic miR-93 promotes the pathogenesis of metabolic dysfunction-associated steatotic liver disease by suppressing SIRT1.
   Metabolism. 2025;169:156266.
   PubMed     Abstract available
   
   
   
10. MUND C, Sinha A, Aderhold A, Mateska I, et al
    A key role of polyamine metabolism in adipose tissue homeostasis that regulates obesity.
    Metabolism. 2025 Aug 1:156358. doi: 10.1016/j.metabol.2025.156358.
    PubMed     Abstract available
    
    
    July 2025
11. EL KOUCHE S, Meyre D
    Natural selection signatures of 65 syndromic and 8 monogenic obesity genes in 7 ethnic groups do not support the thrifty genotype hypothesis.
    Metabolism. 2025 Jul 23:156353. doi: 10.1016/j.metabol.2025.156353.
    PubMed     Abstract available
    
    
    
12. KASAHARA K, Ichikawa Y, Hironaka J, Shinozaki T, et al
    Time for a change? Threshold for obesity in contemporary Japanese population.
    Metabolism. 2025 Jul 15:156352. doi: 10.1016/j.metabol.2025.156352.
    PubMed     Abstract available
    
    
    June 2025
13. KATSAROU A, Papadopoulos G, Moustakas II, Papadopetraki A, et al
    Exercise mitigates liver senescence but does not outmatch dietary restriction in obesity-related MASLD.
    Metabolism. 2025 Jun 10:156325. doi: 10.1016/j.metabol.2025.156325.
    PubMed     Abstract available
    
    
    
14. HINDSO M, Lundsgaard A, Marinkovic B, Jensen MH, et al
    Fat absorption and metabolism after Roux-en-Y gastric bypass surgery.
    Metabolism. 2025;167:156189.
    PubMed     Abstract available
    
    
    May 2025
15. GALAN A, Garcia-Garcia F
    Revisiting gender differences in obesity and type 2 diabetes: Response letter.
    Metabolism. 2025 May 29:156307. doi: 10.1016/j.metabol.2025.156307.
    PubMed    
    
    
    
16. SON YL, Hou J, Kato-Suzuki M, Okamatsu-Ogura Y, et al
    Corrigendum to "Eva1 deficiency prevents obesity-induced metabolic disorders by reducing visceral adipose dysfunction" [Metabolism 168 (2025) 156235].
    Metabolism. 2025;170:156299.
    PubMed    
    
    
    
17. ZHU H, Yi X, He M, Wu S, et al
    Exploring the interplay of genetic variants and environmental factors in childhood obesity: A systematic review and meta-analysis.
    Metabolism. 2025;170:156303.
    PubMed     Abstract available
    
    
    April 2025
18. LENG S, Zhang X, Zhao R, Jiang N, et al
    Mechanical activation of adipose tissue macrophages mediated by Piezo1 protects against diet-induced obesity by regulating sympathetic activity.
    Metabolism. 2025 Apr 7:156262. doi: 10.1016/j.metabol.2025.156262.
    PubMed     Abstract available
    
    
    
19. ZHONG Y, Wei J, Jiang R
    Revisiting gender differences in obesity and type 2 diabetes: Letter to the editor.
    Metabolism. 2025 Apr 3:156260. doi: 10.1016/j.metabol.2025.156260.
    PubMed    
    
    
    March 2025
20. MOLDOVAN RA, Hidalgo MR, Castane H, Jimenez-Franco A, et al
    Landscape of sex differences in obesity and type 2 diabetes in subcutaneous adipose tissue: a systematic review and meta-analysis of transcriptomics studies.
    Metabolism. 2025 Mar 27:156241. doi: 10.1016/j.metabol.2025.156241.
    PubMed     Abstract available
    
    
    
21. RIBAS-LATRE A, Hoffmann A, Gebhardt C, Weiner J, et al
    The serine protease KLK7 promotes immune cell infiltration in visceral adipose tissue in obesity.
    Metabolism. 2025;168:156239.
    PubMed     Abstract available
    
    
    
22. SON YL, Hou J, Kato-Suzuki M, Okamatsu-Ogura Y, et al
    Eva1 deficiency prevents obesity-induced metabolic disorders by reducing visceral adipose dysfunction.
    Metabolism. 2025 Mar 19:156235. doi: 10.1016/j.metabol.2025.156235.
    PubMed     Abstract available
    
    
    
23. ZHANG T, Ren Z, Mao R, Yi W, et al
    LINC00278 and BRG1: A key regulatory axis in male obesity and preadipocyte adipogenesis.
    Metabolism. 2025 Mar 17:156194. doi: 10.1016/j.metabol.2025.156194.
    PubMed     Abstract available
    
    
    
24. KARAKASIS P, Patoulias D, Fragakis N, Mantzoros CS, et al
    Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.
    Metabolism. 2025;164:156113.
    PubMed     Abstract available
    
    
    
25. ZENG X, Wang Y, Farias K, Rappa A, et al
    NRH, a potent NAD(+) enhancer, improves glucose homeostasis and lipid metabolism in diet-induced obese mice through an active adenosine kinase pathway.
    Metabolism. 2025;164:156110.
    PubMed     Abstract available
    
    
    January 2025
26. HU Y, Hai J, Ti Y, Kong B, et al
    Adipose ZFP36 protects against diet-induced obesity and insulin resistance.
    Metabolism. 2025;164:156131.
    PubMed     Abstract available
    
    
    
27. HE Y, Zhang C, Wu S, Li K, et al
    Central NUCB2/nesfatin-1 signaling ameliorates liver steatosis through suppression of endoplasmic reticulum stress in the hypothalamus.
    Metabolism. 2025;162:156046.
    PubMed     Abstract available
    
    
    December 2024
28. MELA V, Martin-Reyes F, Oliva-Olivera W, Cantarero-Cuenca A, et al
    Serum miR-365b-5p/miR-222-5p as a potential diagnostic biomarker for long-term weight loss in patients with morbid obesity after bariatric surgery.
    Metabolism. 2024 Dec 30:156129. doi: 10.1016/j.metabol.2024.156129.
    PubMed     Abstract available
    
    
    
29. PERAKAKIS N, Mantzoros CS
    Evidence from clinical studies of leptin: current and future clinical applications in humans.
    Metabolism. 2024;161:156053.
    PubMed     Abstract available
    
    
    
30. STEFANAKIS K, Kokkorakis M, Mantzoros CS
    The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.
    Metabolism. 2024;161:156057.
    PubMed     Abstract available
    
    
    
31. MUNZBERG H, Heymsfield SB, Berthoud HR, Morrison CD, et al
    History and future of leptin: Discovery, regulation and signaling.
    Metabolism. 2024;161:156026.
    PubMed     Abstract available
    
    
    November 2024
32. BUCHWALD LM, Neess D, Hansen D, Doktor TK, et al
    Body weight control via protein kinase CK2: diet-induced obesity counteracted by pharmacological targeting.
    Metabolism. 2024;162:156060.
    PubMed     Abstract available
    
    
    
33. ZHANG H, Zhou XD, Shapiro MD, Lip GYH, et al
    Global burden of metabolic diseases, 1990-2021.
    Metabolism. 2024;160:155999.
    PubMed     Abstract available
    
    
    October 2024
34. CONFORTO R, Rizzo V, Russo R, Mazza E, et al
    Advances in body composition and gender differences in susceptibility to frailty syndrome: Role of osteosarcopenic obesity.
    Metabolism. 2024 Oct 26:156052. doi: 10.1016/j.metabol.2024.156052.
    PubMed     Abstract available
    
    
    
35. SERRANO J, Kondo S, Link GM, Brown IS, et al
    A partial loss-of-function variant (Ile191Val) of the TAS1R2 glucose receptor is associated with enhanced responses to exercise training in older adults with obesity: A translational study.
    Metabolism. 2024 Oct 9:156045. doi: 10.1016/j.metabol.2024.156045.
    PubMed     Abstract available
    
    
    September 2024
36. XIE Z, Zheng G, Liang Z, Li M, et al
    Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
    Metabolism. 2024 Sep 19:156038. doi: 10.1016/j.metabol.2024.156038.
    PubMed     Abstract available
    
    
    
37. BAGHERI M, Tanriverdi K, Iafrati MD, Mosley JD, et al
    Characterization of the plasma metabolome and lipidome in response to sleeve gastrectomy and gastric bypass surgeries reveals molecular patterns of surgical weight loss.
    Metabolism. 2024;158:155955.
    PubMed     Abstract available
    
    
    August 2024
38. LIM JH, Kim Y, Kim MY, Kim EN, et al
    Placental growth factor deficiency initiates obesity- and aging-associated metabolic syndrome.
    Metabolism. 2024 Aug 20:156002. doi: 10.1016/j.metabol.2024.156002.
    PubMed     Abstract available
    
    
    July 2024
39. RICHTER MM, Kemp IM, Heeboll S, Winther-Sorensen M, et al
    Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms.
    Metabolism. 2024;156:155915.
    PubMed     Abstract available
    
    
    June 2024
40. JOLLET M, Tramontana F, Jiang LQ, Borg ML, et al
    Diacylglycerol kinase delta overexpression improves glucose clearance and protects against the development of obesity.
    Metabolism. 2024 Jun 4:155939. doi: 10.1016/j.metabol.2024.155939.
    PubMed     Abstract available
    
    
    May 2024
41. HUTTASCH M, Roden M, Kahl S
    Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
    Metabolism. 2024 May 21:155937. doi: 10.1016/j.metabol.2024.155937.
    PubMed     Abstract available
    
    
    
42. AVENDANO MS, Perdices-Lopez C, Guerrero-Ruiz Y, Ruiz-Pino F, et al
    The evolutionary conserved miR-137/325 tandem mediates obesity-induced hypogonadism and metabolic comorbidities by repressing hypothalamic kisspeptin.
    Metabolism. 2024 May 8:155932. doi: 10.1016/j.metabol.2024.155932.
    PubMed     Abstract available
    
    
    
43. NEDELCUT S, Axer S, Olbers T
    The risk and benefit of revisional vs. primary metabolic- bariatric surgery and drug therapy - A narrative review.
    Metabolism. 2024;154:155799.
    PubMed     Abstract available
    
    
    April 2024
44. ZELJKOVIC A, Vekic J, Stefanovic A
    Obesity and dyslipidemia in early life: Impact on cardiometabolic risk.
    Metabolism. 2024;156:155919.
    PubMed     Abstract available
    
    
    
45. AWAZAWA M, Matsushita M, Nomura I, Kobayashi N, et al
    Imeglimin improves systemic metabolism by targeting brown adipose tissue and gut microbiota in obese model mice.
    Metabolism. 2024;153:155796.
    PubMed     Abstract available
    
    
    
46. ROSENDO-SILVA D, Gomes PB, Rodrigues T, Viana S, et al
    Clinical and molecular profiling of human visceral adipose tissue reveals impairment of vascular architecture and remodeling as an early hallmark of dysfunction.
    Metabolism. 2024;153:155788.
    PubMed     Abstract available
    
    
    March 2024
47. PENDERGRAST LA, Ashcroft SP, Ehrlich AM, Treebak JT, et al
    Metabolic plasticity and obesity-associated changes in diurnal postexercise metabolism in mice.
    Metabolism. 2024 Mar 11:155834. doi: 10.1016/j.metabol.2024.155834.
    PubMed     Abstract available
    
    
    
48. MENG M, Cao Y, Qiu J, Shan G, et al
    Zinc finger protein ZNF638 regulates triglyceride metabolism via ANGPTL8 in an estrogen dependent manner.
    Metabolism. 2024;152:155784.
    PubMed     Abstract available
    
    
    
49. KOKKINOS A, Tsilingiris D, Simati S, Stefanakis K, et al
    Bariatric surgery, through beneficial effects on underlying mechanisms, improves cardiorenal and liver metabolic risk over an average of ten years of observation: A longitudinal and a case-control study.
    Metabolism. 2024;152:155773.
    PubMed     Abstract available
    
    
    
50. REGMI P, Young M, Minigo G, Milic N, et al
    Photoperiod and metabolic health: evidence, mechanism, and implications.
    Metabolism. 2024;152:155770.
    PubMed     Abstract available
    
    
    
51. LAVILLE M, Robert M, Segrestin B
    Barriers to metabolic surgery and how to address them.
    Metabolism. 2024;152:155764.
    PubMed     Abstract available
    
    
    February 2024
52. RACHELLE H, Malak G, Houry P, Marc H, et al
    Mortality risk in patients with obesity and COVID-19 infection: a systematic review and meta-analysis.
    Metabolism. 2024 Feb 13:155812. doi: 10.1016/j.metabol.2024.155812.
    PubMed     Abstract available
    
    
    
53. SARABHAI T, Kahl S, Gancheva S, Mastrototaro L, et al
    Loss of mitochondrial adaptation associates with deterioration of mitochondrial turnover and structure in metabolic dysfunction-associated steatotic liver disease.
    Metabolism. 2024;151:155762.
    PubMed     Abstract available
    
    
    
54. SAMARASINGHE SNS, Woods C, Miras AD
    Bariatric Surgery in Women with Polycystic Ovary Syndrome.
    Metabolism. 2024;151:155745.
    PubMed     Abstract available
    
    
    
55. TSILINGIRIS D, Kokkinos A
    Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond.
    Metabolism. 2024;151:155741.
    PubMed     Abstract available
    
    
    
56. MURPHY E, Finucane FM
    Addressing uncertainty about the role of structured lifestyle modification for metabolic surgery patients.
    Metabolism. 2024;151:155739.
    PubMed     Abstract available
    
    
    
57. BAUZA-THORBRUGGE M, Vujicic M, Chanclon B, Palsdottir V, et al
    Adiponectin stimulates Sca1(+)CD34(-)-adipocyte precursor cells associated with hyperplastic expansion and beiging of brown and white adipose tissue.
    Metabolism. 2024;151:155716.
    PubMed     Abstract available
    
    
    January 2024
58. FUKUSHIMA T, Maetani T, Chubachi S, Tanabe N, et al
    Epicardial adipose tissue measured from analysis of adipose tissue area using chest CT imaging is the best potential predictor of COVID-19 severity.
    Metabolism. 2024;150:155715.
    PubMed     Abstract available
    
    
    
59. ZIQUBU K, Dludla PV, Mabhida SE, Jack BU, et al
    Brown adipose tissue-derived metabolites and their role in regulating metabolism.
    Metabolism. 2024;150:155709.
    PubMed     Abstract available
    
    
    October 2023
60. KATSAROU A, Kouvari M, Hill MA, Mantzoros CS, et al
    Metabolically unhealthy obesity, sarcopenia and their interactions in obesity pathophysiology and therapeutics: Room for improvement in pharmacotherapy.
    Metabolism. 2023 Oct 27:155714. doi: 10.1016/j.metabol.2023.155714.
    PubMed    
    
    
    
61. STEINBACH E, Masi D, Ribeiro A, Serradas P, et al
    Upper small intestine microbiome in obesity and related metabolic disorders: A new field of investigation.
    Metabolism. 2023 Oct 24:155712. doi: 10.1016/j.metabol.2023.155712.
    PubMed     Abstract available
    
    
    
62. KARAKASIS P, Patoulias D, Pamporis K, Stachteas P, et al
    Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.
    Metabolism. 2023 Oct 16:155710. doi: 10.1016/j.metabol.2023.155710.
    PubMed     Abstract available
    
    
    
63. TSUKAMOTO S, Suzuki T, Wakui H, Uehara T, et al
    Angiotensin II type 1 receptor-associated protein in immune cells: a possible key factor in the pathogenesis of visceral obesity.
    Metabolism. 2023;149:155706.
    PubMed     Abstract available
    
    
    
64. ULLAH R, Shen Y, Zhou YD, Fu J, et al
    Perinatal metabolic inflammation in the hypothalamus impairs the development of homeostatic feeding circuitry.
    Metabolism. 2023;147:155677.
    PubMed     Abstract available
    
    
    September 2023
65. KOKKORAKIS M, Katsarou A, Katsiki N, Mantzoros CS, et al
    Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery.
    Metabolism. 2023;148:155689.
    PubMed     Abstract available
    
    
    
66. CHEN W, Cui W, Wu J, Zheng W, et al
    Blocking IL-6 signaling improves glucose tolerance via SLC39A5-mediated suppression of glucagon secretion.
    Metabolism. 2023;146:155641.
    PubMed     Abstract available
    
    
    August 2023
67. POLYZOS SA, Vachliotis ID, Mantzoros CS
    Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease.
    Metabolism. 2023 Aug 4:155676. doi: 10.1016/j.metabol.2023.155676.
    PubMed     Abstract available
    
    
    
68. HOFFMANN A, Meir AY, Hagemann T, Czechowski P, et al
    A polyphenol-rich green Mediterranean diet enhances epigenetic regulatory potential: the DIRECT PLUS randomized controlled trial.
    Metabolism. 2023;145:155594.
    PubMed     Abstract available
    
    
    
69. PARK SH, Helsley RN, Fadhul T, Willoughby JLS, et al
    Fructose induced KHK-C can increase ER stress independent of its effect on lipogenesis to drive liver disease in diet-induced and genetic models of NAFLD.
    Metabolism. 2023;145:155591.
    PubMed     Abstract available
    
    
    July 2023
70. FERNANDEZ-SAEZ EM, Losarcos M, Becerril S, Valenti V, et al
    Uroguanylin prevents hepatic steatosis, mitochondrial dysfunction and fibrosis in obesity-associated NAFLD.
    Metabolism. 2023 Jul 28:155663. doi: 10.1016/j.metabol.2023.155663.
    PubMed     Abstract available
    
    
    
71. MUTURI HT, Ghadieh HE, Abdolahipour R, Stankus HL, et al
    Loss of CEACAM1 in endothelial cells causes hepatic fibrosis.
    Metabolism. 2023;144:155562.
    PubMed     Abstract available
    
    
    June 2023
72. KOSCHKER AC, Warrings B, Morbach C, Seyfried F, et al
    Effect of bariatric surgery on cardio-psycho-metabolic outcomes in severe obesity: A randomized controlled trial.
    Metabolism. 2023 Jun 30:155655. doi: 10.1016/j.metabol.2023.155655.
    PubMed     Abstract available
    
    
    
73. JUNG EJ, Sung KW, Bae TH, Kim HY, et al
    The N-degron pathway mediates lipophagy: The chemical modulation of lipophagy in obesity and NAFLD.
    Metabolism. 2023 Jun 27:155644. doi: 10.1016/j.metabol.2023.155644.
    PubMed     Abstract available
    
    
    
74. AXELROD CL, Dantas WS, Kirwan JP
    Sarcopenic obesity: emerging mechanisms and therapeutic potential.
    Metabolism. 2023 Jun 26:155639. doi: 10.1016/j.metabol.2023.155639.
    PubMed     Abstract available
    
    
    
75. WEI F, Gu Y, He L, Kapoor A, et al
    HSD17B6 delays type 2 diabetes development via inhibiting SREBP activation.
    Metabolism. 2023;145:155631.
    PubMed     Abstract available
    
    
    
76. BOUTARI C, Hill MA, Procaccini C, Matarese G, et al
    The key role of inflammation in the pathogenesis and management of obesity and CVD.
    Metabolism. 2023 Jun 9:155627. doi: 10.1016/j.metabol.2023.155627.
    PubMed    
    
    
    
77. OH J, Park C, Kim S, Kim M, et al
    High levels of intracellular endotrophin in adipocytes mediate COPII vesicle supplies to autophagosome to impair autophagic flux and contribute to systemic insulin resistance in obesity.
    Metabolism. 2023 Jun 9:155629. doi: 10.1016/j.metabol.2023.155629.
    PubMed     Abstract available
    
    
    
78. DE OLIVEIRA MC, Silveira ALM, de Oliveira ACC, Lana JP, et al
    Eosinophils protect from metabolic alterations triggered by obesity.
    Metabolism. 2023 Jun 7:155613. doi: 10.1016/j.metabol.2023.155613.
    PubMed     Abstract available
    
    
    
79. LIU B, Zhong Y, Huang D, Yang L, et al
    LncRNA Nron deficiency protects mice from diet-induced adiposity and hepatic steatosis.
    Metabolism. 2023 Jun 3:155609. doi: 10.1016/j.metabol.2023.155609.
    PubMed     Abstract available
    
    
    
80. WANG H, Xiong Q, He G, Tang J, et al
    Hepatic IDH2 regulates glycolysis and gluconeogenesis.
    Metabolism. 2023;143:155559.
    PubMed     Abstract available
    
    
    
81. BARAZZONI R, Cederholm T, Zanetti M, Gortan Cappellari G, et al
    Defining and diagnosing sarcopenia: Is the glass now half full?
    Metabolism. 2023;143:155558.
    PubMed     Abstract available
    
    
    
82. BRETHVAD AO, Zakariassen HL, Holt J, Lundgren JR, et al
    Increased meal-induced neurotensin response predicts successful maintenance of weight loss - Data from a randomized controlled trial.
    Metabolism. 2023;143:155534.
    PubMed     Abstract available
    
    
    May 2023
83. CAPPELLARI GG, Semolic A, Zanetti M, Vinci P, et al
    Sarcopenic obesity in free-living older adults detected by the ESPEN-EASO consensus diagnostic algorithm: Validation in an Italian cohort and predictive value of insulin resistance and altered plasma ghrelin profile.
    Metabolism. 2023 May 26:155595. doi: 10.1016/j.metabol.2023.155595.
    PubMed     Abstract available
    
    
    
84. JAVAID HMA, Ko E, Joo EJ, Kwon SH, et al
    TNFalpha-induced NLRP3 inflammasome mediates adipocyte dysfunction and activates macrophages through adipocyte-derived lipocalin 2.
    Metabolism. 2023;142:155527.
    PubMed     Abstract available
    
    
    April 2023
85. PARK MJ, Choi KM
    Interplay of skeletal muscle and adipose tissue: sarcopenic obesity.
    Metabolism. 2023 Apr 29:155577. doi: 10.1016/j.metabol.2023.155577.
    PubMed     Abstract available
    
    
    
86. GUO X, Hu J, He G, Chen J, et al
    Loss of APOO (MIC26) aggravates obesity-related whitening of brown adipose tissue via PPARalpha-mediated functional interplay between mitochondria and peroxisomes.
    Metabolism. 2023 Apr 21:155564. doi: 10.1016/j.metabol.2023.155564.
    PubMed     Abstract available
    
    
    
87. CHONG B, Kong G, Shankar K, Chew HSJ, et al
    The global syndemic of metabolic diseases in the young adult population: A consortium of trends and projections from the Global Burden of Disease 2000-2019.
    Metabolism. 2023;141:155402.
    PubMed     Abstract available
    
    
    
88. REBELOS E, Mari A, Oikonen V, Iida H, et al
    Evaluation of renal glucose uptake with [(18)F]FDG-PET: Methodological advancements and metabolic outcomes.
    Metabolism. 2023;141:155382.
    PubMed     Abstract available
    
    
    March 2023
89. PAPADOPOULOS G, Legaki AI, Georgila K, Vorkas P, et al
    Integrated omics analysis for characterization of the contribution of high fructose corn syrup to non-alcoholic fatty liver disease in obesity.
    Metabolism. 2023 Mar 28:155552. doi: 10.1016/j.metabol.2023.155552.
    PubMed     Abstract available
    
    
    
90. BIANZANO S, Henrich A, Herich L, Kalsch B, et al
    Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies.
    Metabolism. 2023 Mar 21:155550. doi: 10.1016/j.metabol.2023.155550.
    PubMed     Abstract available
    
    
    
91. XU H, Yu W, Sun M, Bi Y, et al
    Syntaxin17 contributes to obesity cardiomyopathy through promoting mitochondrial Ca(2+) overload in a Parkin-MCUb-dependent manner.
    Metabolism. 2023 Mar 20:155551. doi: 10.1016/j.metabol.2023.155551.
    PubMed     Abstract available
    
    
    
92. LUO X, Li Z, Chen L, Zhang X, et al
    Monocarboxylate transporter 1 in the liver modulates high-fat diet-induced obesity and hepatic steatosis in mice.
    Metabolism. 2023 Mar 16:155537. doi: 10.1016/j.metabol.2023.155537.
    PubMed     Abstract available
    
    
    
93. MARLENE C, Christos MS
    Advances in physiology, design and development of novel medications changing the landscape of obesity pharmacotherapy.
    Metabolism. 2023 Mar 2:155531. doi: 10.1016/j.metabol.2023.155531.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Obesity is free of charge.